USD
$0.00
(0.00%
)At Close (As of Sep 5, 2025)
$430.51B
Market Cap
19.06
P/E Ratio
9.38
EPS
$179.84
52 Week High
$137.37
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $61B |
Total Revenue | $89B |
Cost Of Revenue | $27B |
Costof Goods And Services Sold | $27B |
Operating Income | $22B |
Selling General And Administrative | $22B |
Research And Development | $17B |
Operating Expenses | $67B |
Investment Income Net | - |
Net Interest Income | $577M |
Interest Income | $1.3B |
Interest Expense | $755M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $7.3B |
Income Before Tax | $17B |
Income Tax Expense | $2.6B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $14B |
Comprehensive Income Net Of Tax | - |
Ebit | $17B |
Ebitda | $25B |
Net Income | $14B |
Field | Value (USD) |
---|---|
Total Assets | $180B |
Total Current Assets | $56B |
Cash And Cash Equivalents At Carrying Value | $24B |
Cash And Short Term Investments | $24B |
Inventory | $12B |
Current Net Receivables | $15B |
Total Non Current Assets | $124B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $38B |
Intangible Assets Excluding Goodwill | $38B |
Goodwill | $44B |
Investments | - |
Long Term Investments | - |
Short Term Investments | $417M |
Other Current Assets | - |
Other Non Current Assets | - |
Total Liabilities | $109B |
Total Current Liabilities | $50B |
Current Accounts Payable | $10B |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $6B |
Total Non Current Liabilities | $58B |
Capital Lease Obligations | - |
Long Term Debt | $31B |
Current Long Term Debt | $6B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $37B |
Other Current Liabilities | $30B |
Other Non Current Liabilities | $18B |
Total Shareholder Equity | $71B |
Treasury Stock | - |
Retained Earnings | - |
Common Stock | - |
Common Stock Shares Outstanding | $2.4B |
Field | Value (USD) |
---|---|
Operating Cashflow | $24B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $7.3B |
Capital Expenditures | $4.4B |
Change In Receivables | - |
Change In Inventory | -$1.1B |
Profit Loss | - |
Cashflow From Investment | -$19B |
Cashflow From Financing | -$3.1B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $12B |
Dividend Payout Common Stock | $12B |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$2.4B |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $14B |
Field | Value (USD) |
---|---|
Gross Profit | $61B |
Total Revenue | $89B |
Cost Of Revenue | $27B |
Costof Goods And Services Sold | $27B |
Operating Income | $22B |
Selling General And Administrative | $22B |
Research And Development | $17B |
Operating Expenses | $67B |
Investment Income Net | - |
Net Interest Income | $577M |
Interest Income | $1.3B |
Interest Expense | $755M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $7.3B |
Income Before Tax | $17B |
Income Tax Expense | $2.6B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $14B |
Comprehensive Income Net Of Tax | - |
Ebit | $17B |
Ebitda | $25B |
Net Income | $14B |
Field | Value |
---|---|
Ex Dividend Date | 2025-08-26 |
Declaration Date | 2025-07-16 |
Record Date | 2025-08-26 |
Payment Date | 2025-09-09 |
Amount | 1.3 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.